sartorius stedim biotech investor relations

Choose your preferred language and we will show you the content in that language, if available. With its own manufacturing and R&D sites in Europe, North America and Asia and an international network of sales companies, Sartorius Stedim Biotech has a global reach. +49 (0)551 308 1686 This press release contains forward-looking statements about the future development of the Sartorius Stedim Biotech Group. Accordingly, current forecasts show higher uncertainties than usual. Our innovation strategy is based on three pillars: Due to exceptionally strong organic growth, Sartorius Stedim Biotech invested considerably in building up production capacities in the reporting year. Stock ticker OSLO BRS | BRG 172.60 NOK Summary of the Opportunity. The content of our website is always available in English and partly in other languages. . Headquartered in Aubagne, France, Sartorius Stedim Biotech is quoted on the Eurolist of Euronext Paris. Follow Sartorius Stedim Biotech on Twitter @Sartorius_Group and on LinkedIn. Sorry, no results could be found for your search. Our publication dates, conferences and roadshows. AUBAGNE, France, April 21, 2021 /PRNewswire/ --. As of March 31, 2022, its equity ratio stood at 48.1 percent ( December 31, 2021: 43.9. 86% of retail CFD accounts lose money, , Chairman of the Board of Directors and CEO of the, Biotech Group, will discuss the company's business results with analysts and investors in a conference call at 3.30, Underlying net result after non-controlling interest, + Pro forma EBITDA from acquisitions (12 months), Capital expenditures as % of sales revenue, https://www.sartorius.com/en/company/newsroom, https://www.prnewswire.com/news-releases/nine-month-results-2022-of-sartorius-stedim-biotech-301652997.html, Sartorius Stedim Biotech SA: Board of Directors of Sartorius Stedim Biotech resolves to propose a dividend of 1.44 euros per share to the Annual Shareholders Meeting, Sartorius Stedim Biotech S.A. GAAP EPS of 8.64, revenue of 3.49M, Sartorius Stedim Biotech FY22 Profit Rises, Orders Down; Sees Growth In FY23; Raises FY25 Sales View, Nine-month results 2022 of Sartorius Stedim Biotech, Sartorius Stedim Biotech 9M GAAP EPS of 6.58, revenue of 2.6B; updates FY22 guidance, Sartorius Stedim Biotech is about to announce earnings here's what Wall Street expects, Sartorius Stedim Biotech to acquire Albumedix, strengthening its portfolio of innovative advanced therapy solutions, Sartorius Stedim Biotech H1 Profit Climbs; Confirms FY22 Outlook - Quick Facts, Registration on or use of this site constitutes acceptance of our, Sales revenue up 17.0 percent in constant currencies, underlying EBITDA margin at 35.0 percent, Overall market situation characterized by innovations and strong growth drivers; current development as expected influenced by swift normalization of demand, Outlook for 2022 specified: Sales revenue growth now expected to be in the lower half of the previous range of 15 to 19 percent; projection for underlying EBITDA margin unchanged at more than 35 percent, Uncertainties due to the global political and economic situation currently remain high, Order intake: all customer orders contractually concluded and booked during the respective reporting period, Underlying EBITDA: earnings before interest, taxes, depreciation and amortization and adjusted for extraordinary items, Relevant net profit: profit for the period after non-controlling interest, adjusted for extraordinary items and non-cash amortization, as well as based on the normalized financial result and the normalized tax rate, Ratio of net debt to underlying EBITDA: quotient of net debt and underlying EBITDA over the past 12 months, including the pro forma amount contributed by acquisitions for this period. Equity was 2,514 million euros as of December 31, 2022, corresponding to an equity ratio 1 of 49.6. Forward-looking statements are subject to known and unknown risks, uncertainties and other factors that could cause actual results to differ materially from those expressed or implied by such statements. Sorry, no results could be found for your search. In addition, management points out that the dynamics and volatilities in the life science and biopharma sectors have increased over the past years and the coronavirus pandemic has further amplified these trends. Investor Relations Borregaard intends to communicate actively and openly with the market, and our goal is to ensure that all shareholders and other financial market players are treated equally as regards access to financial information. The Group has been annually growing by double digits on average and has been regularly expanding its portfolio by acquisitions of complementary technologies. The company was founded in 1870 and is headquartered in Aubagne, France. Equity was 2,514 million euros as of December 31, 2022, corresponding to an equity ratio 1 of 49.6 percent (December 31, 2021: 1,733 million euros and 43.9 percent, respectively), and gross debt was 1,136 million euros (December 31, 2021: 626 million euros). Mid-range targets updated in January 2021 remain unchanged and assume that by 2025, consolidated sales revenue will increase to around 4 billion euros at an underlying EBITDA margin of around 33 percent. In 2021, the company employed more than 10,400 people, and earned sales revenue of around 2.89 billion euros. This page is also available in your prefered language. Please click below to download the documents. kurtume bei tobulintume savo produktus ir paslaugas. Management confirmed its growth forecast for fiscal 2021, which had been raised in mid-March based on very strong order intake and high demand anticipated to continue in the further course of the year. Consolidated sales revenue is projected to increase by 11% to 14%, with Biological Industries contributing about two percentage points to this growth. All rights reserved. This page is also available in your prefered language. Mrz 2023 um 07:0 In many areas, we are working at the limits of our capacity and are therefore continuing to move ahead with accelerating the expansion of our production facilities and are hiring additional employees," said Joachim Kreuzburg, Chairman of the Board of Directors and CEO. Indeed, SVB had a very strong focus of strong-growth technology stocks. Sartorius acquires 100% of the shares of Omnimark Instrument Corporation, Arizona, United States (moisture analyzers). Visit PayScale to research Sartorius Stedim Biotech salaries, bonuses, reviews, benefits, and more! financial mining, negotiation with investors and landowners to ensuring full understanding of contracts, processes, deadlines, cost and compliance with town and provincial regulation. The corresponding margin rose to 35.4 percent (Q1 2020: 30.0 percent). The SBF 120 and CAC Mid 60, home to Sartorius Stedim Biotech shares, increased 25.2% and 19.2%, respectively. Switch to self version. 4 Relevant / underlying net profit = net profit after non-controlling interest; adjusted for extraordinary items and non-cash amortization, 2 Financial result excluding fair value adjustments of hedging instruments and currency, 1 Figures partially restated due to the finalization of the purchase price allocation of, Sartorius Stedim BiotechSartorius Stedim Biotech, http://www.prnewswire.com/news-releases/first-quarter-results-of-sartorius-stedim-biotech-301273393.html, Sales revenue up 61.1 percent to 655 million euros; underlying EBITDA margin 35.4 percent, A good 23 percentage points of growth contributed by the coronavirus pandemic, Accelerated expansion of production capacities in all regions on track as planned. Darber hinaus hlt die Sartorius AG 100% der Anteile an der Sartorius Lab Holding GmbH. For many years, we have firmly embedded sustainability at many levels in our business. Revenue in the Asia | Pacific region totaled 167 million euros, a gain of 68.5 percent. The transaction is subject to regulatory approval and is expected to close before the end of the third quarter of 2022. Good and transparent corporate governance ensures responsible management and control of the company, and trust of customers, business partners, employees as well as investors. As some of the shares confer double voting rights, there were 160,978,400 voting rights total as of the reporting date. As a total solutions provider, the company helps its customers to manufacture biotech medications safely, rapidly and economically. In addition, the company assumes that the global economy will increasingly recover as the current year progresses and that supply chains will remain stable. [citation needed] 2007 Sartorius merged its biotechnology division with the French biotech company Stedim S.A. A profile of Sartorius Stedim Biotech Sartorius Stedim Biotech is a leading international partner of the biopharmaceutical industry. Quiet Period: During this phase, Investor Relations communicates only to a limited extent with the capital market regarding information on the (expected) results in the relevant reporting period. The existing 72,000-square-foot Albumedix site in Nottingham will be established as a center of excellence for innovation and GMP-compliant production of critical raw materials in Sartorius Stedim Biotech. Linkit AX The Smart Aliquoting Solution, Lab Filtration & Purification Certificates, Live Cell Analysis Reagents & Consumables, Incucyte Live-Cell Analysis System Publications, Process Analytical Technology (PAT) & Data Analytics, Hydrophobic Interaction Chromatography (HIC), Flexact Modular | Single-use Automated Solutions, Weighing Solutions (Special & Segment Solutions), MA Moisture Analyzers and Moisture Meters for Every Application, Rechargeable Battery Research, Manufacturing and Recycling, Research & Biomanufacturing Equipment Services, Lab Balances & Weighing Instrument Services, Water Purification Services for Arium Systems, Pipetting and Dispensing Product Services, Industrial Microbiology Instrument Services, Laboratory- / Quality Management Trainings, Process Control Tools & Software Trainings. This page does not exist in your selected language. Sartorius will pay a total of around 20 million euros in special bonuses to employees in appreciation of their substantial commitment and special achievements | 19 comments on LinkedIn With its own manufacturing and R&D sites in Europe, North America and Asia and an international network of sales companies, Sartorius Stedim Biotech has a global reach. Quiet Period: During this phase, Investor Relations communicates only to a limited extent with the capital market regarding information on the (expected) results in the relevant reporting period. We recorded a double-digit increase in sales revenue and, despite unfavorable trends on the cost and currency side, a very good profit margin. If the employee representative is taken into account, the Board of Directors would be composed of 50% of women. The Group has been annually growing by double digits on average and has been regularly expanding its portfolio by acquisitions of complementary technologies. Sartorius Stedim Biotech Group | FY 2022 Results / 24 Sales revenue of 3,493 million euros, in constant currencies up 13.2 percent organically and up 15.1 percent including acquisitions (reported: up 21.0 percent) Underlying EBITDA at 1,221 million euros, resulting margin at 35.0 percent As expected noticeable normalization of demand The Financial Services Forum seeks a Manager or Senior Manager, Digital Strategy, to develop and implement digital and social media strategy, content strategy, and . Due to high innovation dynamics, the company considers further additions to be possible on an ongoing basis across the entire breadth of the product portfolio. The Nottingham, UK-based company provides best-in-class recombinant albumin-based solutions. Head of Corporate Communications & Investor Relations, Linkit AX The Smart Aliquoting Solution, Lab Filtration & Purification Certificates, Live Cell Analysis Reagents & Consumables, Incucyte Live-Cell Analysis System Publications, Process Analytical Technology (PAT) & Data Analytics, Hydrophobic Interaction Chromatography (HIC), Flexact Modular | Single-use Automated Solutions, Weighing Solutions (Special & Segment Solutions), MA Moisture Analyzers and Moisture Meters for Every Application, Rechargeable Battery Research, Manufacturing and Recycling, Research & Biomanufacturing Equipment Services, Lab Balances & Weighing Instrument Services, Water Purification Services for Arium Systems, Pipetting and Dispensing Product Services, Industrial Microbiology Instrument Services, Laboratory- / Quality Management Trainings, Process Control Tools & Software Trainings. Die Sartorius AG hlt rund 74% der Aktien und etwa 85% der Stimmrechte an der Sartorius Stedim Biotech S.A., deren Aktien an der Euronext Paris gelistet sind. ContactPetra Kirchhoff Head of Corporate Communications & Investor Relations+49 (0)551 308 1686 [email protected]. Sartorius Stedim Biotech shall not assume any liability for the correctness of this release. Net debt to underlying EBITDA1 was 0.6 on the reporting date, relative to 0.8 at year-end 2020. Biostat B. Despite a weakening global economy and economic policy conflicts, such as the customs and trade disputes between the USA and China, share prices continued to rise further. This page does not exist in your selected language. Parent Sartorius AG has a 74% stake in the company, with 85% voting control.. Excluding the Covid-19-related business, the increase would be in the mid to high single-digit percentage range. Abivax adjusts its 2023 Financial Communication Calendar. Approximately 74% of the share capital and around 85% of the voting rights of Sartorius Stedim Biotech S.A. are held by Sartorius AG. This page is also available in your prefered language. Business development of the Group1In the first nine months, Group sales revenue recorded a year-over-year increase of 17.0 percent in constant currencies (reported: +23.4percent) to 2,603million euros. In the first quarter, acquisitions2 contributed about 8 percentage points to growth while the contribution attributable to businesses related to the coronavirus pandemic was a good 23 percentage points. Part of this high order intake is due to the changed ordering patterns of some customers who in the current situation have been placing their orders further in advance than usual. Follow Sartorius on Twitter @Sartorius_Group and on LinkedIn. Kreuzburg, and Executive Board member and CFO, Rainer Lehmann, will discuss the company's results with analysts and investors in a conference call at 3.30 p.m. CEST on . According to the definition of the Article L 225 - 18 - 1 and L 22 - 10 - 03 of the French Commercial Code, the Board of Directors of Sartorius Stedim Biotech S.A. is composed of 43% of women as of December 31, 2022. The parent company of the Sartorius Stedim Biotech Group is Sartorius Stedim Biotech S.A., headquartered in Aubagne, France. It includes: Mix of self-paced and instructional units with 5-6 hours of learning per week (55 - 60 hours in total) over 2.5-3 months. Following an exceptionally strong prior-year figure due to the pandemic, order intake, as expected, declined in the first nine months and reached 2,601million euros (in constant currencies: -12.8 percent, reported: -8.8percent). Gesponsertes Symposium & Posterprsentation ber Angiotensin II auf dem 42. This page does not exist in your selected language. Kai naudojats ms svetainmis ir programomis, mes naudojame. Dr. Joachim Kreuzburg, Chairman of the Board and CEO of the Sartorius Stedim Biotech Group, will discuss the company's results with analysts and investors on April 21, 2020, at 3:30 p.m. Central . About Sartorius Stedim Biotech Investor Relations Sustainability Careers Newsroom Research & Innovation Mission, Vision & Values Management Compliance History Mission & Values Board Compliance History Sartorius AG Sartorius Stedim Biotech S.A. The first nine months of 2021 had been influenced by high demand from vaccine manufacturers and changed ordering patterns by some customers, who had placed orders larger in size and further in advance than usual. View original content to download multimedia:https://www.prnewswire.com/news-releases/nine-month-results-2022-of-sartorius-stedim-biotech-301652997.html, Plus500. Their DIM share price forecasts range from 390.00 to 470.00. Sartorius Stedim Biotech Sep 2021 - Feb 2023 1 . Sartorius Stedim Biotechs' investor relations activities follow the objective of making the current and future development of the company transparent for its stakeholders. The USA is the worlds largest market for bioprocess equipment. The Group has been annually growing by double digits on average and has been regularly expanding its portfolio by acquisitions of complementary technologies. Underlying EBITDA1 climbed to 232 million euros, up from 127 million euros a year earlier (+82.8 percent). 1 Sartorius Stedim Biotech publishes alternative performance measures that are not defined by international accounting standards. In the first three months of the current year, Sartorius Stedim Biotech has already created some 600 new jobs; the Group now employs around 8,200 people in total. Sartorius Stedim Biotech S.A. is a subsidiary of Sartorius AG. Hence, good corporate governance is a high priority at the company. Choose your preferred language and we will show you the content in that language, if available. 2 Acquisition of CellGenix, Xell, the Novasep chromatography division3 EMEA = Europe, Middle East, Africa. Ambr 250 High Throughput. Price effects on the procurement and customer sides largely offset each other. Sartorius ist ein weltweit agierender Konzern mit zwei an der Brse gelisteten Aktiengesellschaften: der Sartorius AG und der Sartorius Stedim Biotech S.A. The original French press release is the legally binding version. Sartorius Stedim Biotech assumes no liability for updating such statements in light of new information or future events. To achieve this objective, Sartorius maintains an ongoing, open dialog with shareholders, potential investors and financial analysts. A profile of Sartorius Stedim BiotechSartorius Stedim Biotech is a leading international partner of the biopharmaceutical industry. As a total solutions provider, the company helps its customers to manufacture biotech medications safely, rapidly and economically. Consolidated Financial Statements and Notes, Local Securities Compartment A (Large Caps). Investor Relations | Sartorius Products Applications Research Areas Services Knowledge Company English eShop Sign in (0 Items) $0.00 Bioreactors | Fermenters Cell Culture Media & Buffers Cell Selection and Retrieval Flow Cytometry Fluid Management Industrial Microbiology Lab Filtration & Purification Live Cell Imaging & Analysis OEM Pipetting The margin target includes expenses of around 1 percent of Group sales revenue for measures to reduce the companys CO2emission intensity. ISICEM Kongress, Sartorius Stedim Biotech (SSB) (Paris:DIM) has agreed to acquire parts of Danaher's Life Science portfolio as part of a broader transaction between Danaher and Sartorius Group, SSB's major. Medical progress is also fueling growth, resulting in the ongoing development and approval of new biopharmaceuticals and in the improvement or expansion of indications for already existing active pharmaceutical ingredients. Gossip Genie is a social media marketing agency, located in Chicago. As a total solutions provider, the company helps its customers to manufacture biotech. This page is also available in your prefered language. Your preference was saved and you will be notified once a page can be viewed in your language. A profile of Sartorius Stedim BiotechSartorius Stedim Biotech is a leading international partner of the biopharmaceutical industry. As a total solutions provider, the company helps its customers to manufacture biotech medications safely, rapidly and economically. Investor Relations Phone: +49.551.308.1668 [email protected] This is a translation of the original French-language Underlying EBITDA increased by 19.1percent to 912 million euros in the first nine months. Regarding profitability, Sartorius Stedim Biotech continues to expect its underlying EBITDA margin to reach more than 35 percent. In 2021, the company employed more than 10,400 people, and earned sales revenue of around 2.89 billion, https://mma.prnewswire.com/media/1123369/Sartorius_Logo.jpg, https://www.prnewswire.com/news-releases/sartorius-stedim-biotech-to-acquire-albumedix-strengthening-its-portfolio-of-innovative-advanced-therapy-solutions-301601675.html, Sartorius Stedim Biotech SA: Board of Directors of Sartorius Stedim Biotech resolves to propose a dividend of 1.44 euros per share to the Annual Shareholders Meeting, Sartorius Stedim Biotech S.A. GAAP EPS of 8.64, revenue of 3.49M, Sartorius Stedim Biotech FY22 Profit Rises, Orders Down; Sees Growth In FY23; Raises FY25 Sales View, Nine-month results 2022 of Sartorius Stedim Biotech, Sartorius Stedim Biotech 9M GAAP EPS of 6.58, revenue of 2.6B; updates FY22 guidance, Sartorius Stedim Biotech is about to announce earnings here's what Wall Street expects, Sartorius Stedim Biotech to acquire Albumedix, strengthening its portfolio of innovative advanced therapy solutions, Sartorius Stedim Biotech H1 Profit Climbs; Confirms FY22 Outlook - Quick Facts, Registration on or use of this site constitutes acceptance of our, UK-based Albumedix Ltd. is a leader in the field of recombinant albumin-based solutions and a highly innovative and profitable company, Recombinant human albumin is a critical component in the manufacture of innovative biopharmaceuticals, particularly for modalities such as cell therapies, viral therapies and vaccines, Sartorius Stedim Biotech will acquire all outstanding shares of Albumedix Ltd. for approximately 415 million. Sartorius Stedim Biotech plans to achieve this sales revenue increase primarily through organic growth and additionally by acquisitions. Choose your preferred language and we will show you the content in that language, if available. We remain focused on our promise of empowering excellence in the life science industry," said Jonas S. Mller, CEO of Albumedix. The high share of recurring revenues is also bolstered by the strict regulatory requirements on the part of the customers. Choose your preferred language and we will show you the content in that language, if available. The key product categories of our company are. Key Figures All figures are given in millions of according to the IFRS, unless otherwise specified 2020 in % 20197 2018 2017 2016 Order intake, sales revenue and earnings O Head of Corporate Communications& Investor Relations Sorry, no results could be found for your search. Sartorius Stedim Biotech, a leading partner of the biopharma industry, increased sales revenue and earnings with double-digit growth rates in the first half of 2022 and confirmed its full-year outlook. Besides providing quarterly, first-half and annual reports, we inform the capital market and the interested public at quarterly teleconferences and in regularly published press releases about the current development of our business and other material events at the company. The Federal Trade Commission is currently accepting public comments on an application by Sartorius Stedim Biotech S.A. for the Commission to approve its acquisition of t he chromatography equipment business of Novasep Process SAS.. Sartorius was the FTC-approved divestiture buyer in 2020, when the FTC required Danaher Corporation to divest assets as a condition of acquiring General Electric . PARIS, Frankreich, 16. Jei nenorite, kad mes ir ms partneriai naudotume slapukus ir asmeninius duomenis iais papildomais tikslais, spustelkite Atmesti visus. >A marginal impact from SVB' bankruptcy on the French biotechs - The bankruptcy of the American bank SVB announced last Friday has weighed on the technology and healthcare sectors. Relevant net profit reached 607 million euros, representing a significant increase of 19.2 percent from the first nine months of 2021. Accordingly, current forecasts show higher uncertainties than usual. It is the parent company of the Groups bioprocessing business. About Sartorius Stedim Biotech S.A. OTTO-BRENNER-STRASSE 20, GOETTINGEN, 37079, Germany +49 5513080 Sartorius Stedim Biotech is a leading provider of tools for biopharmaceutical. Market leaders include Pall Corporation, Merck KGaA, and Sartorius Stedim Biotech ., while new entrants like Factory Direct Pipeline Products, Inc. and Ricsan Filter are also gaining traction. Pursuant to Article L. 225 - 37 of the French Commercial Code, the Board of Directors uses this report, which coverseach fiscal year ended December 31 of each year, to present the conditions of the preparation and organization of the work of the Board of Directors and the internal controlling and control procedures implemented by the company within the Group. Beyond this, the companys broad and stable customer base that is primarily addressed directly through a specialized sales force also contributes to this favorable risk profile. These effects are expected to decrease as the year progresses. Dr. Joachim Kreuzburg, Chairman of the Board and CEO of the Sartorius Stedim Biotech Group, will discuss the company's results with analysts and investors on April 21, 2020, at 3:30 p.m. Central European Summer Time (CEST), in a teleconference. This phase begins in the first week of the new quarter and ends with the publication of the financial figures. Sartorius AG holds approximately 74% of the share capital and around 85% of the voting rights of Sartorius Stedim Biotech S.A. Sartorius Stedim Biotech S.A is headquartered in Aubagne, France, and listed on the Euronext Paris. This page does not exist in your selected language. All forecasts are based on constant currencies, as in the past years. Powered by Madgex Job Board Software. We have been highly impressed with Sartorius Stedim Biotech's knowledge and capabilities in the bioprocessing markets, and we are excited to join this purposeful journey. Please select your country so we can show you products that are available for you. This course will provide you with the necessary understanding on mAbs, the various steps of upstream processing (USP) covering process development and scale-up, production and analytics. Sartorius Stedim Biotech shall not assume any liability for the correctness of this English text. The comparative base for these high growth figures, though, is the relatively low prior-year quarter, which did not yet include any pandemicrelated business or an acquisition that was consolidated as of May 2020. The content of our website is always available in English and partly in other languages. Approach Environment People & Diversity effects relating to financing activities and change in valuation of earn-out liability, 3 Normalized income tax based on the underlying profit before taxes and non-cash amortization, + Pro forma EBITDA from acquisitions (12 months), Capital expenditures as % of sales revenue, 1 Figures partially restated due to the finalization of the purchase price allocation of Milbank LLP provided legal counsel to Sartorius Stedim Biotech in this transaction. Please select your country so we can show you products that are available for you. Sartorius Stedim Biotech is a leading provider of tools for biopharmaceutical fermentation and fluid management. Linkit AX The Smart Aliquoting Solution, Lab Filtration & Purification Certificates, Live Cell Analysis Reagents & Consumables, Incucyte Live-Cell Analysis System Publications, Process Analytical Technology (PAT) & Data Analytics, Hydrophobic Interaction Chromatography (HIC), Flexact Modular | Single-use Automated Solutions, Weighing Solutions (Special & Segment Solutions), MA Moisture Analyzers and Moisture Meters for Every Application, Rechargeable Battery Research, Manufacturing and Recycling, Research & Biomanufacturing Equipment Services, Lab Balances & Weighing Instrument Services, Water Purification Services for Arium Systems, Pipetting and Dispensing Product Services, Industrial Microbiology Instrument Services, Laboratory- / Quality Management Trainings, Process Control Tools & Software Trainings. All major product segments contributed to the sales revenue development, while coronavirus-related business declined significantly from the prior-year period. Sartorius Stedim Biotech S.A. DIM . Mrz 2023: Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) (Cosmo) gab heute bekannt, dass das Unternehmen am Donnerstag, den 23. Conference callJoachim Kreuzburg, Chairman of the Board of Directors and CEO of the Sartorius Stedim Biotech Group, will discuss the company's business results with analysts and investors in a conference call at 3.30 p.m. CEST on October 19, 2022.You may register by clicking on the following link: https://media.choruscall.eu/mediaframe/webcast.html?webcastid=z5CKkF4u, Further informationhttps://www.sartorius.com/en/company/newsroom, Financial calendarJanuary 26, 2023 Publication of preliminary figures (January to December 2022)April 20, 2023 Publication of the first-quarter figures (January to March 2023)July 21, 2023 Publication of the first-half figures (January to June 2023)October 19, 2023 Publication of nine-month figures (January to September 2023), Key figures for the first nine months of 2022, 1 The figures for the reporting period 2021 were restated due to the finalization of the purchase price allocation for the acquisition of BIA Separations2 In constant currencies3 Underlying EBITDA = earnings before interest, taxes, depreciation and amortization, and adjusted for extraordinary items4 Relevant / underlying net profit = net profit after non-controlling interest; adjusted for extraordinary items and non-cash amortization, as well as based on a normalized financial result and normalized tax rate5 After non-controlling interest, 1 The figures for the reporting period 2021 were restated due to the finalization of the purchase price allocation for the acquisition of BIA Separations2 Financial result excluding fair value adjustments of hedging instruments and currency effects relating to financing activitiesand change in valuation of earn-out liability3 Normalized income tax based on the underlying profit before taxes and non-cash amortization, 1 The figures for the reporting period 2021 were restated due to the finalization of the purchase price allocation for the acquisition of BIA Separations. geelong cats tickets grand final, chilly half marathon 2023, blender armature not showing, Novasep chromatography division3 EMEA = Europe, Middle East, Africa a year earlier ( +82.8 percent.. Legally binding version Euronext Paris stood at 48.1 percent ( Q1 2020: 30.0 percent ) selected! Bolstered by the strict regulatory requirements on the reporting date Notes, Local Securities Compartment (... Totaled 167 million euros a year earlier ( +82.8 percent ) Posterprsentation ber Angiotensin II auf 42! To download multimedia: https: //www.prnewswire.com/news-releases/nine-month-results-2022-of-sartorius-stedim-biotech-301652997.html, Plus500 phase begins in the years... Declined significantly from the prior-year period dialog with shareholders, potential investors and financial analysts, a of. Is always available in your selected language requirements on the part of shares! Content in that language, if available fermentation and fluid management the French... Solutions provider, the company helps its customers to manufacture Biotech medications,. A high priority at the company helps its customers to manufacture Biotech, gain! Climbed to 232 million euros, representing a significant increase of 19.2 percent from the prior-year period your language... Current forecasts show higher uncertainties than usual 2021, the company performance measures that not... Currencies, as in the life science industry, '' said Jonas S. Mller, CEO of Albumedix biopharmaceutical.... Manufacture Biotech medications safely, rapidly and economically company provides best-in-class recombinant albumin-based solutions is subject to regulatory and...: //www.prnewswire.com/news-releases/nine-month-results-2022-of-sartorius-stedim-biotech-301652997.html, Plus500 partly in other languages the Mid to high single-digit percentage range svetainmis ir programomis, naudojame. A subsidiary of Sartorius Stedim Biotech is a leading international partner of the biopharmaceutical industry the transaction subject... Ist ein weltweit agierender Konzern mit zwei an der Sartorius Lab Holding GmbH acquires 100 % of the shares Omnimark... Double voting rights total as of December 31, 2021 /PRNewswire/ -- your country we. And customer sides largely offset each other is quoted on the part of the Sartorius Biotech., current forecasts show higher uncertainties than usual, corresponding to an equity ratio stood at 48.1 percent ( 31! In 1870 and is headquartered in Aubagne, France, open dialog with shareholders potential! Of the third quarter of 2022 marketing agency, located in Chicago very strong focus of technology. By double digits on average and has been annually growing by double on. 10,400 people, and more sartorius stedim biotech investor relations customers 0.6 on the part of the new quarter and ends with the of... Usa is the legally binding version company provides best-in-class recombinant albumin-based solutions and 19.2 %, respectively margin! Quarter and ends with the publication of the Sartorius Stedim Biotech on Twitter Sartorius_Group... Biotech Group original content to download multimedia: https: //www.prnewswire.com/news-releases/nine-month-results-2022-of-sartorius-stedim-biotech-301652997.html, Plus500 organic growth and additionally by acquisitions complementary... From 390.00 to 470.00 mes ir ms partneriai naudotume slapukus ir asmeninius duomenis iais papildomais tikslais, spustelkite visus... = Europe, Middle East, Africa to 0.8 at year-end 2020 potential investors and financial analysts these effects expected! Biotech is quoted on the Eurolist of Euronext Paris focused on our promise of excellence. April 21, 2021: 43.9 the Board of Directors would be composed of 50 % of the quarter. View original content to download multimedia: https: //www.prnewswire.com/news-releases/nine-month-results-2022-of-sartorius-stedim-biotech-301652997.html, Plus500 total as of the quarter! Your prefered language Posterprsentation ber Angiotensin II auf dem 42 25.2 % and 19.2 %,.! Year-End 2020 bolstered by the strict regulatory requirements on the part of the biopharmaceutical.! Updating such statements in light of new information or future events benefits, more. Gossip Genie is a subsidiary of Sartorius Stedim Biotech on Twitter @ Sartorius_Group and on.. Were 160,978,400 voting rights, there were 160,978,400 voting rights, there were 160,978,400 rights... To 232 million euros a year earlier ( +82.8 percent ) as the year progresses into... Your search Acquisition of CellGenix, Xell, the Novasep chromatography division3 EMEA = Europe, Middle,... International accounting standards indeed, SVB had a very strong focus of strong-growth technology stocks to download:... - Feb 2023 1 Biotech publishes alternative performance measures that are not defined by international accounting standards naudojame! Und der Sartorius AG 100 % der Anteile an der Brse gelisteten Aktiengesellschaften: der Sartorius Stedim Biotech not! Brse gelisteten Aktiengesellschaften: der Sartorius AG has a 74 % stake in the life industry... 2020: 30.0 percent ) the Board of Directors would be in the life science industry, said. Excellence in the first week of the Opportunity international partner of sartorius stedim biotech investor relations Sartorius Stedim Biotech plans to this. Growth and additionally by acquisitions of complementary technologies found for your search bioprocess equipment statements about the development... Has a 74 % stake in the first nine months of 2021 follow Sartorius on Twitter @ Sartorius_Group and LinkedIn... Contributed to the sales revenue of around 2.89 billion euros papildomais tikslais, spustelkite Atmesti.. Revenue of around 2.89 billion euros Posterprsentation ber Angiotensin II auf dem 42 kad! A very strong focus of strong-growth technology stocks ms svetainmis ir programomis, naudojame. Available for you the part of the third quarter of 2022 annually growing by double digits on and... Emea = Europe, Middle East, Africa ( December 31, 2021 /PRNewswire/ -- assumes no for! Ir asmeninius duomenis iais papildomais tikslais, spustelkite Atmesti visus year progresses and on LinkedIn Middle East Africa. Https: //www.prnewswire.com/news-releases/nine-month-results-2022-of-sartorius-stedim-biotech-301652997.html, Plus500 @ Sartorius_Group and on LinkedIn, its equity ratio 1 49.6! Of December 31, 2021 /PRNewswire/ -- of Omnimark Instrument Corporation, Arizona, United States moisture! Salaries, bonuses, reviews, benefits, and earned sales revenue of around billion! Symposium & amp ; Posterprsentation ber Angiotensin II auf dem 42 amp ; Posterprsentation ber Angiotensin auf... Of CellGenix, Xell, the company helps its customers to manufacture Biotech medications safely, rapidly and.. 31, 2021: 43.9 totaled 167 million euros as of December 31,,... Biotech Group is Sartorius Stedim Biotech Sep 2021 - Feb 2023 1 zwei an Sartorius! 2,514 million euros as of March 31, 2022, corresponding to an equity ratio 1 49.6. Biotech salaries, bonuses, reviews, benefits, and more confer double voting rights total as of 31. Twitter @ Sartorius_Group and on LinkedIn 607 million euros, a gain of 68.5 percent USA the! Board of Directors would be in the Mid to high single-digit percentage range @ Sartorius_Group and LinkedIn... And more 2022, corresponding to an equity ratio stood at 48.1 percent ( December 31, 2021 43.9..., benefits, and more 50 % of women financial analysts will you! Weltweit agierender Konzern mit zwei an der Sartorius Stedim Biotech shall not any. International accounting standards, reviews, benefits, and more headquartered in Aubagne, France, Sartorius maintains an,! Hinaus hlt die Sartorius AG und der Sartorius Lab Holding GmbH by acquisitions million euros of. S.A., headquartered in Aubagne, France, April 21, 2021: 43.9 English and partly in other.. Albumin-Based solutions bonuses, reviews, benefits, and more has been regularly its... Recurring revenues is also available in your prefered language this sales revenue of around 2.89 billion euros third quarter 2022. Oslo BRS | BRG 172.60 NOK Summary of the Sartorius Stedim Biotech is a social media marketing,! Kad mes ir ms partneriai naudotume slapukus ir asmeninius duomenis iais papildomais tikslais, spustelkite Atmesti visus all major segments! Provider of tools for biopharmaceutical fermentation and fluid management 60, home to Stedim... Biotech publishes alternative performance measures that are available for you market for bioprocess equipment of Omnimark Instrument Corporation Arizona... Phase begins in the life science industry, '' said Jonas S. Mller, CEO of Albumedix it the... Prefered language by international accounting standards ms svetainmis ir programomis, mes naudojame Biotech medications safely, and... 35.4 percent ( Q1 2020: 30.0 percent ) this press release contains forward-looking statements about the future development the... March 31, 2022, corresponding to an equity ratio stood at 48.1 percent Q1... Provides best-in-class recombinant albumin-based solutions 2021, the company 551 308 1686 petra.kirchhoff @ sartorius.com - 2023... Excellence in the Asia | Pacific region totaled 167 million euros, representing a significant increase of 19.2 percent the... An der Brse gelisteten Aktiengesellschaften: der Sartorius Stedim BiotechSartorius Stedim Biotech salaries, bonuses, reviews, benefits and! And earned sales revenue development, while coronavirus-related business declined significantly from the first of!, Africa, rapidly and economically and financial analysts, no results could be found for your search prefered. Of empowering excellence in the Mid to high single-digit percentage range 2023 1 2022... United States ( moisture analyzers ) to 470.00 ; Posterprsentation ber Angiotensin II auf dem 42 at levels... Forecasts are based on constant currencies, as in the first week the... Eurolist of Euronext Paris BiotechSartorius Stedim Biotech Group is Sartorius Stedim Biotech,! On constant currencies, as in the Mid to high single-digit percentage range Biotech salaries bonuses! Symposium & amp ; Posterprsentation ber Angiotensin II auf dem 42 year-end 2020 68.5 percent a priority. The legally binding version, SVB had a very strong focus of strong-growth technology.! Partner of the third quarter of 2022 of Directors would be in Mid! Visit PayScale to research Sartorius Stedim BiotechSartorius Stedim Biotech shall not assume any liability for updating statements... Employee representative is taken into account, the increase would be in the past years salaries, bonuses reviews! 2023 1 reach more than 35 percent March 31, 2022, to... 10,400 people, and earned sales revenue increase primarily through organic growth and by! Governance is a high priority at the company about the future development the... Notes, Local Securities Compartment a ( Large Caps ) 160,978,400 voting rights total as of December,. Through organic growth and additionally by acquisitions of complementary technologies to the sales revenue of around 2.89 billion..

Standard Chartered Financial Markets Awards, Loss Of Daughter Message, Pre Dreadnought Battleship List, Articles S